Is SLS or SMMT more undervalued in 2026?

CirclFi compares SELLAS Life Sciences Group, Inc (SLS) and Summit Therapeutics Inc. (SMMT) using 13 institutional-grade valuation models. SLS has a Quality of Company score of 4.1/10 while SMMT scores 4.4/10.

Which is a better buy — SLS or SMMT?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do SLS and SMMT valuations compare?

SLS at $9.18 and SMMT at $17.41 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

SLS vs SMMT Valuation Comparison 2026 — Intrinsic Value Analysis

SLS

Biotechnology

SELLAS Life Sciences Group, Inc

Quality

4.1

out of 10

Value Trap

SAFE

Price

$9.18

Last close

Models

7/13

Active

SMMT

Biotechnology

Summit Therapeutics Inc.

Quality

4.4

out of 10

Value Trap

SAFE

Price

$17.41

Last close

Models

12/13

Active

Model-by-Model Comparison

Model	Type	SLS Fair Value	SLS Upside	SMMT Fair Value	SMMT Upside
Bayesian DCF	Intrinsic	$2.78	-69.8%	$5.97	-65.7%
Earnings Power Value	Intrinsic	—	—	$10.70	-51.5%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$0.65	-92.9%	$0.86	-95.0%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for SLS vs SMMT — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

SLS vs SMMT — Which Stock Is More Undervalued?

SMMT scores higher with a 4.4/10 quality rating vs SLS's 4.1/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing SELLAS Life Sciences Group, Inc (SLS) and Summit Therapeutics Inc. (SMMT) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

SLS currently trades at $9.18 with a QOC of 4.1/10, while SMMT trades at $17.41 with a QOC of 4.4/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).